-
First person vaccinated during trial of new Ebola jab
-
More than 80,000 flee forest infernos in France and Spain
-
Iryna Terekh: the trained architect behind Ukraine's deep-strike drones
-
Tens of thousands in France flee burning holiday haven, by road and sea
-
At least 21 killed in Russian and Ukrainian long-range strikes
-
Maresca says it's a 'privilege' to succeed Guardiola at Man City
-
Stock markets recover as oil retreats
-
Dutchman van Bommel appointed new Belgium football coach
-
US singer Chris Brown admits new brawl charge, avoids UK trial
-
Russia after Putin: The ‘parliament with a one-per-cent chance’
-
'Cockroach' protest leaders, India govt say no breakthrough in talks
-
Two wildfires merge near Madrid, 19,000 evacuated or confined
-
Leclerc on top for Ferrari but suffers car failure
-
Peaty begins quest for more Commonwealth gold, Aussie swimmers set for bonus
-
UK PM Burnham back in Manchester to kickstart English 'devolution'
-
US singer Chris Brown admits new affray charge, avoids UK trial
-
Autonomous fighter jets target Europe market at Farnborough airshow
-
MEXC Expands Ondo Tokenized Stock Offerings with AI Infrastructure and Mining Assets
-
Antonelli has his neck on the line with ever watchful father
-
At least 17 killed in Russian and Ukrainian long-range strikes
-
Firefighters race to stop wildfires merging near Madrid
-
Wildberries: Russia's Amazon that became a target for Kyiv
-
UN urges evacuation of 6,000 sailors stranded in Hormuz strait
-
Oil prices retreat after surge, as stock markets diverge
-
Thousands flee wildfires in France, Spain
-
Volkswagen profits skid on one-off costs, China competition
-
Joshua's focus on Prenga as Fury lies in wait
-
Spain coach blasts 'unacceptable' behaviour of Argentina after World Cup final
-
Klopp handed task of reviving Germany's football fortunes
-
India's youth-led 'Cockroach' movement holds new round of talks with govt
-
Rugby brain injury court case at risk of collapse
-
Some 40,000 people evacuated due to wildfire in southwest France: minister
-
Recharged Klopp back to turn Germany from doubters into believers
-
Philippines says ship hit by Chinese water cannon at disputed reef
-
Baby monkey Punch to celebrate first birthday
-
Fires in Europe: latest developments
-
Thousands flee wildfires in southern Europe
-
Ukraine hits 'Russia's Amazon' warehouses outside St Petersburg
-
South Korean tycoon ordered to pay $644m in divorce
-
Wrestling to become a man in Togo's ancestral rite of passage
-
Hundreds flee French peninsula by boat to escape wildfire
-
WAFCON favourites Nigeria eye World Cup slot and record prize money
-
Brian Lara Stadium hosts maiden Test as West Indies face Pakistan
-
Socceroos star Volpato allegedly tests positive for cocaine
-
Volkswagen profit plunges as carmaker weighs mass job cuts
-
Ukraine drone attack hits 'Russia's Amazon' warehouse
-
India protest leaders to meet govt after Modi vows action
-
US imposes new tariffs on 60 partners as Trump rebuilds trade agenda
-
Fear, arrests keep Cambodians quiet decade after critic's murder
-
Stocks suffer fresh blow as markets hit by perfect storm
First person vaccinated during trial of new Ebola jab
A volunteer was injected on Friday with the first dose of a rapidly developed vaccine targeting the Bundibugyo strain of Ebola driving a deadly outbreak in the Democratic Republic of Congo, Oxford University said.
More than 1,000 people have been killed in the DRC and Uganda since the outbreak emerged in May, according to the World Health Organization.
Researchers and health organisations have since been racing to get a vaccine or treatment for the relatively rare strain to the clinical trial stage where it is tested on humans.
Earlier this month, a team at Oxford University in the UK announced it was launching the first trial for its ChAdOx1 BDBV vaccine, which uses the same technology as AstraZeneca's Covid-19 vaccine.
The first dose was administered to a 37-year-old volunteer named Ed Hunt in Oxford on Friday, a university spokesman told AFP.
"We've taken this vaccine candidate from concept to clinic in just eight weeks," David Pulido-Gomez of Oxford's Pandemic Sciences Institute said in a statement.
"Reaching this milestone in such a short timeframe reflects an extraordinary collaborative effort," he added.
The trial received funding from the Coalition for Epidemic Preparedness Innovations (CEPI), while the Serum Institute of India has already manufactured a stockpile of 620,000 doses.
The phase 1 trial plans to assess the safety and effectiveness of the vaccine in 50 health adults in the coming weeks. The researchers are currently recruiting more volunteers.
Given regulatory approval, the team is preparing for more clinical studies of the vaccine with partners in Uganda, Oxford said.
Several other Bundibugyo vaccine candidates are also being urgently developed towards the trial stage, while two potential treatments are being worked on.
The Ebola outbreak is the 17th in the DRC's history, but just the third caused by the Bundibugyo strain, for which there are no approved vaccines or treatments.
WHO chief Tedros Adhanom Ghebreyesus warned last week that the outbreak had over the past month "expanded faster than any previous outbreak" of Ebola.
The outbreak has remained concentrated in the vast country's mineral-rich and conflict-plagued northeastern province.
Cases of Ebola, which spreads through close contact and infected bodily fluids, have also been found in four other DRC provinces.
T.Sanchez--AT